Grades 3 and 4 adverse events · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma probably leads to higher adverse events at grades 3 to 4 up to 28 days compared with saline placebo (moderate certainty).
1 finding from 1 review
RR 4.09 [1.39, 12.01]
Studies not reported
Moderate
Serious adverse events up to day 28 (data available only as a composite of serious adverse events or death up to day 28) · individuals with moderate or severe COVID‐19
Hyperimmune immunoglobulin from human plasma showed no clear difference in serious adverse events up to day 28 (data available only as a… compared with saline placebo (low certainty).
1 finding from 1 review
RR 0.72 [0.45, 1.14]
Studies not reported
Low
Use of ET (≥ 1); all studies · neonates with alloimmune hemolytic disease
It is very uncertain whether intravenous immunoglobulin plus phototherapy changes use of ET (≥ 1); all studies compared with phototherapy alone (very low certainty).
1 finding from 1 review
Use of ET (≥ 1); placebo‐controlled studies · neonates with alloimmune hemolytic disease
Intravenous immunoglobulin plus phototherapy showed no clear difference in use of ET (≥ 1); placebo‐controlled studies compared with phototherapy alone (moderate certainty).
1 finding from 1 review
ETs performed per infant; all studies · neonates with alloimmune hemolytic disease
1 finding from 1 review
ETs performed per infant; placebo‐controlled studies · neonates with alloimmune hemolytic disease
1 finding from 1 review
Use of top‐up transfusion in 1st week of life; all studies · neonates with alloimmune hemolytic disease
Intravenous immunoglobulin plus phototherapy showed no clear difference in use of top‐up transfusion in 1st week of life; all studies compared with phototherapy alone (low certainty).
1 finding from 1 review
Use of top‐up transfusion after 1st week of life; all studies · neonates with alloimmune hemolytic disease
It is very uncertain whether intravenous immunoglobulin plus phototherapy changes use of top‐up transfusion after 1st week of life; all studies compared with phototherapy alone (very low certainty).
1 finding from 1 review
Maximum total serum bilirubin (µmol/L); all studies · neonates with alloimmune hemolytic disease
1 finding from 1 review
All‐cause mortality, neonates, standard polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in all‐cause mortality, neonates, standard polyclonal IVIG compared with placebo or no intervention (moderate certainty).
2 findings from 1 review
All‐cause mortality, neonates, IgM‐enriched polyclonal IVIG · neonates with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) showed no clear difference in all‐cause mortality, neonates, IgM‐enriched polyclonal IVIG compared with placebo or no intervention (low certainty).
1 finding from 1 review
28‐Day all cause mortality (adult studies) · adult patients with sepsis, severe sepsis and septic shock
Polyclonal intravenous immunoglobulin (IVIG) probably leads to lower all‐cause mortality, adults, standard polyclonal IVIG compared with placebo or no intervention (moderate certainty).
5 findings from 1 review
RR 0.81 [0.7, 0.93]
10 studies · 1430 participants
Moderate
RR 0.66 [0.51, 0.85]
7 studies · 528 participants
Moderate
RR 0.97 [0.81, 1.15]
5 studies · 945 participants
High
Show 2 more findings
Death · adults with renal vasculitis
Intravenous immunoglobulin showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
Kidney function · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dialysis · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Response at 3 months · adults with renal vasculitis
Intravenous immunoglobulin may leads to higher response at 3 months compared with placebo (low certainty).
1 finding from 1 review
Relapse at 3 months · adults with renal vasculitis
Intravenous immunoglobulin showed no clear difference in relapse at 3 months compared with placebo (low certainty).
1 finding from 1 review
Adverse events · adults with renal vasculitis
Intravenous immunoglobulin may leads to higher adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious infection · adults with renal vasculitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
SAEs · NSTI
Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).
1 finding from 1 review